Asymmetry Capital Management as of June 30, 2017
Portfolio Holdings for Asymmetry Capital Management
Asymmetry Capital Management holds 28 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ptc Therapeutics I (PTCT) | 11.5 | $9.7M | 528k | 18.33 | |
| Medtronic (MDT) | 6.8 | $5.8M | 65k | 88.75 | |
| Sarepta Therapeutics (SRPT) | 6.3 | $5.4M | 159k | 33.71 | |
| Jazz Pharmaceuticals (JAZZ) | 5.8 | $4.9M | 31k | 155.49 | |
| UnitedHealth (UNH) | 5.7 | $4.8M | 26k | 185.43 | |
| Bio-Rad Laboratories (BIO) | 5.5 | $4.6M | 20k | 226.32 | |
| Nevro (NVRO) | 5.4 | $4.5M | 61k | 74.43 | |
| Centene Corporation (CNC) | 5.3 | $4.5M | 56k | 79.87 | |
| Acadia Healthcare (ACHC) | 4.8 | $4.1M | 83k | 49.37 | |
| Gilead Sciences (GILD) | 4.8 | $4.0M | 57k | 70.79 | |
| Amicus Therapeutics (FOLD) | 4.8 | $4.0M | 402k | 10.07 | |
| Intercept Pharmaceuticals In | 4.2 | $3.6M | 30k | 121.07 | |
| Quest Diagnostics Incorporated (DGX) | 4.0 | $3.4M | 31k | 111.17 | |
| Clovis Oncology | 3.6 | $3.0M | 32k | 93.62 | |
| Inogen (INGN) | 2.4 | $2.0M | 21k | 95.41 | |
| Alder Biopharmaceuticals | 2.3 | $1.9M | 167k | 11.45 | |
| GlaxoSmithKline | 2.2 | $1.9M | 43k | 43.12 | |
| Tactile Systems Technology, In (TCMD) | 2.1 | $1.7M | 61k | 28.58 | |
| Synergy Pharmaceuticals | 2.0 | $1.7M | 373k | 4.45 | |
| DURECT Corporation | 1.9 | $1.6M | 1.0M | 1.56 | |
| Neurocrine Biosciences (NBIX) | 1.9 | $1.6M | 34k | 45.99 | |
| Alexion Pharmaceuticals | 1.8 | $1.5M | 12k | 121.70 | |
| Aerie Pharmaceuticals | 1.6 | $1.3M | 26k | 52.54 | |
| Ironwood Pharmaceuticals (IRWD) | 1.1 | $971k | 51k | 18.88 | |
| Natera (NTRA) | 0.8 | $693k | 64k | 10.86 | |
| Antares Pharma | 0.8 | $643k | 200k | 3.22 | |
| Regenxbio Inc equity us cm (RGNX) | 0.3 | $275k | 14k | 19.78 | |
| Oxford Immunotec Global | 0.3 | $273k | 16k | 16.84 |
